WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today the expansion of its board of directors with the appointment of Mr. Daniel Myers and Mr. Bernard Haffey.
Mr. Myers is currently the President, CEO and co-founder of Alimera Sciences, Inc., a biopharmaceutical company that is developing and commercializing prescription ophthalmic pharmaceuticals. Under his leadership, Alimera has raised venture funding totaling approximately $90M. Myers has over 25 years of experience in the ophthalmic pharmaceutical industry in sales, marketing, and general management. “I am pleased to have the opportunity to contribute to the Ocular Therapeutix Board of Directors. The I-ZIP(R) Ocular Bandage has the potential to be of great benefit to patients in the future,” said Myers.
Mr. Haffey was most recently President and CEO of NDO Surgical, a medical technology company dedicated to the development of innovative endoscopic technologies for gastrointestinal diseases. Prior to this position, he joined IntraLase Corp. as Vice President, Business Development. With over 10 years experience in medical technology, Haffey has a proven track record of successfully launching emerging medical technology and medical device companies. Additionally, he has successfully helped three of his former companies through acquisition including NDO Surgical and Intralase. “I am delighted to be joining the world-class team at Ocular Therapeutix and look forward to helping the company achieve world-class business results,” said Haffey.
“We are extremely fortunate to add industry veterans such as Bernie and Dan to our board. While Bernie brings commercial leadership and expertise particularly in the refractive and corneal areas, Dan has deep expertise in ophthalmic pharmaceutical and drug delivery. Their addition to our team will be key as we move forward towards commercialization of the I-ZIP bandage in the US and as we build our drug delivery programs,” said Amar Sawhney, President and CEO of Ocular Therapeutix. The appointment of Mr. Haffey and Mr. Myers increases the number of Ocular Therapeutix directors to seven. Board members also include Amar Sawhney, Fred Khosravi of Access Closure, Inc., Charles Warden of Versant Ventures, Sam Wu of SV Life Sciences, and Alan Crane of Polaris Ventures.
About Ocular Therapeutix, Inc:
Ocular Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. The company was founded in November 2006. The I-ZIP Adherent Ocular Bandage is CE Mark approved and the I-ZIP Ocular Bandage is under clinical investigation in the United States.
I-ZIP is a registered trademark of Ocular Therapeutix, Inc.
http://www.ocutx.com
SOURCE Ocular Therapeutix, Inc.
CONTACT: William H. Ransone, Ocular Therapeutix, Inc., +1-781-895-3235
Web site: http://www.ocutx.com/
